Deciphering the Epigenetic Role of KDM4A in Pancreatic β-like Cell Differentiation from iPSCs

Pancreatic β cells derived from human induced pluripotent stem cells (hiPSCs) represent a promising therapeutic avenue in regenerative medicine for diabetes treatment. However, current differentiation protocols lack the specificity and efficiency required to reliably produce fully functional β cells, limiting their clinical applicability. Epigenetic barriers, such as histone modifications, may hinder proper differentiation and the acquisition of essential maturation markers in these cells. In this study, we investigated the role of the histone demethylase KDM4A in the differentiation of insulin-producing pancreatic β cells from hiPSCs. KDM4A removes trimethyl groups from lysine residues H3K9 and H3K36, critical epigenetic marks associated with gene regulation. The results showed that Knockdown of KDM4A significantly reduced the expression of pancreatic differentiation genes, such as PDX1, NX6.1, and INS, compared to WT iPSCs differentiated under the same conditions. Similarly, glucose-stimulated insulin secretion was reduced by approximately 80%. These findings underscore the importance of histone demethylation in optimizing differentiation protocols for hiPSC-derived β cells. Our results provide preliminary insights into the epigenetic mechanisms governing β-cell maturation, laying the groundwork for further exploration of histone demethylases as potential targets to enhance regenerative medicine strategies for diabetes treatment.